RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eagle Pharmaceuticals Stock

Eagle Pharmaceuticals ROA 2024

Eagle Pharmaceuticals ROA

0.09

Ticker

EGRX

ISIN

US2697961082

WKN

A1XEDS

In 2024, Eagle Pharmaceuticals's return on assets (ROA) was 0.09, a -358.54% increase from the -0.03 ROA in the previous year.

Eagle Pharmaceuticals Aktienanalyse

What does Eagle Pharmaceuticals do?

Eagle Pharmaceuticals Inc was founded in 2007 and is based in New Jersey, USA. The company operates in the field of development and marketing of pharmaceutical products. History Eagle Pharmaceuticals was founded by Scott Tarriff, an experienced entrepreneur and expert in the fields of pharmacy and biotechnology. The goal was to create a company focused on developing generic drugs with improved effectiveness. Eagle Pharmaceuticals started with two products - Argatroban and Ryanodex. Argatroban is an anticoagulant used in the treatment of thrombosis. Ryanodex is a muscle relaxant for patients suffering from malignant hyperthermia. Business model Eagle Pharmaceuticals has a unique business model that sets it apart from other pharmaceutical companies. They focus on developing generic drugs with improved effectiveness instead of entirely new drugs. The company also focuses on licensing technologies rather than spending money on research and development. The company works closely with doctors and hospitals to ensure that their products meet the needs of patients. Divisions Eagle Pharmaceuticals is divided into two business segments - branded and generic products. Branded products: The company develops and distributes generic products with improved effectiveness. These include products such as Ryanodex, Bendeka, Belrapzo, and Pemetrexed. Generic products: The company has a wide range of generic products used in the areas of anticoagulants, oncology, and pain management. These include products such as Argatroban, Docetaxel, Phenylephrine HCl, and Bivalirudin. Products Argatroban: An anticoagulant used in patients with thrombosis or thromboembolic events. Ryanodex: A muscle relaxant used in patients suffering from malignant hyperthermia. Bendeka: A medication for leukemia used in combination with other chemotherapies. Belrapzo: A medication for certain types of cancer used in combination with other chemotherapies. Pemetrexed: A medication for various cancer diseases, such as lung and breast cancer. Docetaxel: A medication for various cancer diseases, such as breast cancer, lung cancer, and prostate cancer. Phenylephrine HCl: A medication for high blood pressure and bronchodilation. Bivalirudin: An anticoagulant used in patients undergoing angioplasty or coronary bypass surgery. In summary, Eagle Pharmaceuticals is an innovative pharmaceutical company that focuses on developing drugs with improved effectiveness. The company has a wide range of products in the areas of oncology, pain management, and anticoagulants. It works closely with doctors and hospitals to ensure that its products meet the needs of patients. Eagle Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Eagle Pharmaceuticals's Return on Assets (ROA)

Eagle Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Eagle Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Eagle Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Eagle Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Eagle Pharmaceuticals stock

What is the Return on Assets (ROA) of Eagle Pharmaceuticals this year?

The Return on Assets (ROA) of Eagle Pharmaceuticals is 0.09 undefined this year.

What was the ROA of Eagle Pharmaceuticals compared to the previous year?

The ROA of Eagle Pharmaceuticals has increased by -358.54% compared to the previous year.

What consequences do high ROA have for investors of Eagle Pharmaceuticals?

A high ROA is advantageous for investors of Eagle Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Eagle Pharmaceuticals?

A low ROA can be unfavorable for investors of Eagle Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Eagle Pharmaceuticals affect the company?

An increase in ROA of Eagle Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Eagle Pharmaceuticals impact the company?

A reduction in the ROA of Eagle Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Eagle Pharmaceuticals?

Some factors that can influence the ROA of Eagle Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Eagle Pharmaceuticals important for investors?

The ROA of Eagle Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Eagle Pharmaceuticals take to improve ROA?

To improve ROA, Eagle Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Eagle Pharmaceuticals pay?

Over the past 12 months, Eagle Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eagle Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eagle Pharmaceuticals?

The current dividend yield of Eagle Pharmaceuticals is .

When does Eagle Pharmaceuticals pay dividends?

Eagle Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eagle Pharmaceuticals?

Eagle Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eagle Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eagle Pharmaceuticals located?

Eagle Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eagle Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eagle Pharmaceuticals from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Eagle Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Eagle Pharmaceuticals in the year 2023?

In the year 2023, Eagle Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eagle Pharmaceuticals pay out the dividend?

The dividends of Eagle Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eagle Pharmaceuticals

Our stock analysis for Eagle Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eagle Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.